-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Cidara Therapeutics, Raises Price Target to $75

Benzinga·06/24/2025 14:27:42
Listen to the news
RBC Capital analyst Brian Abrahams maintains Cidara Therapeutics (NASDAQ:CDTX) with a Outperform and raises the price target from $35 to $75.